Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05780567
What this trial is testing

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 1,946
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Testing effectiveness (Phase 2)Looking for participantsNCT05455619
What this trial is testing

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Who this might be right for
HR+/HER2-negative Breast CancerMetastatic Breast Cancer
SynDevRx, Inc. 52
Large-scale testing (Phase 3)Looking for participantsNCT07205822
What this trial is testing

Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07333937
What this trial is testing

Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

Who this might be right for
Brest Cancer
Xijing Hospital 35
Testing effectiveness (Phase 2)UnknownNCT03560856
What this trial is testing

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

Who this might be right for
Breast CancerHR+/HER2-negative Breast CancerMetastasis
Assistance Publique - Hôpitaux de Paris 54
Testing effectiveness (Phase 2)UnknownNCT06561022
What this trial is testing

Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping

Who this might be right for
Breast Cancer
Fudan University 260
Not applicableStudy completedNCT01899079
What this trial is testing

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 217
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Testing effectiveness (Phase 2)Study completedNCT02871791
What this trial is testing

Palbociclib With Everolimus + Exemestane In BC

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Dana-Farber Cancer Institute 41
Testing effectiveness (Phase 2)Ended earlyNCT04113863
What this trial is testing

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Who this might be right for
Breast Neoplasm Female
Mario Negri Institute for Pharmacological Research 76
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07102940
What this trial is testing

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

Who this might be right for
Breast CancerHER 2 Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+1 more
George Washington University 50
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Not applicableEnded earlyNCT04396626
What this trial is testing

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

Who this might be right for
Breast Cancer
Pfizer 975
Testing effectiveness (Phase 2)Ended earlyNCT04862143
What this trial is testing

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 2
Large-scale testing (Phase 3)Study completedNCT05054751
What this trial is testing

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd. 275
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Not applicableActive Not RecruitingNCT07692230
What this trial is testing

MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer

Who this might be right for
HR Positive/HER-2 Negative Breast Cancer
Fudan University 2,000
Early research (Phase 1)Study completedNCT02791334
What this trial is testing

Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Who this might be right for
Solid TumorMicrosatellite Instability-High (MSI-H) Solid TumorsCutaneous Melanoma+2 more
Eli Lilly and Company 164
Testing effectiveness (Phase 2)Active Not RecruitingNCT06599216
What this trial is testing

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

Who this might be right for
Breast CancerHR+/HER2- Breast Cancer
Harbin Medical University 30
Next Page